TABLE 4.
Lymphoid | Genotype | CTL (n=6) | 7d (n=5) | 14d (n=4) | 42d (n=4) |
---|---|---|---|---|---|
Total Lymphocytes CD3+ | SPCI73TGATA1WT | 17.33 ± 1.36 | 9.71 ± 2.54 a | 6.43 ± 1.51 a | 20.97 ± 1.14 b , c |
SPCI73TGATA1KO | 12.51 ± 0.85 | 14.58 ± 3.08 | 15.27 ± 1.56 | 21.32 ± 1.26a | |
T Cells CD3+CD4+ | SPCI73TGATA1WT | 9.50 ± 0.60 | 3.64 ± 0.87 a | 2.29 ± 0.42 a | 9.20 ± 0.55 b , c |
SPCI73TGATA1KO | 4.96 ± 0.44 | 6.51 ± 1.48 | 7.90 ± 1.42 | 10.98 ± 0.91 a , b | |
T Cells CD3+CD8+ | SPCI73TGATA1WT | 0.89 ± 0.16 | 1.10 ± 0.28 | 0.22 ± 0.03 | 3.05 ± 1.20 a , c |
SPCI73TGATA1KO | 1.77 ± 0.20 | 1.48 ± 0.23 | 0.85 ± 0.27 | 1.64 ± 0.17 | |
Dendritic Cells CD4+CD103+ | SPCI73TGATA1WT | 0.23 ± 0.02 | 0.21 ± 0.04 | 0.92 ± 0.40 | 0.62 ± 0.14 |
SPCI73TGATA1KO | 0.10 ± 0.01 | 0.81 ± 0.41 | 0.73 ± 0.14 | 0.84 ± 0.07 | |
Dendritic Cells CD8+CD103+ | SPCI73TGATA1WT | 3.36 ± 0.41 | 2.41 ± 0.80 | 0.42 ± 0.11 a | 4.78 ± 0.09 b , c |
SPCI73TGATA1KO | 1.87 ± 0.32 | 2.69 ± 0.58 | 1.28 ± 0.33 | 3.38 ± 0.39 c | |
Total B Cells B220+ | SPCI73TGATA1WT | 20.06 ± 2.95 | 7.38 ± 3.07 a | 3.22 ± 1.15 a | 18.64 ± 1.56 b , c |
SPCI73TGATA1KO | 28.35 ± 2.07 | 12.07 ± 4.08 a | 9.42 ± 1.68 a | 13.67 ± 1.18 a | |
B Cells B220+CX3CR1- | SPCI73TGATA1WT | 8.03 ± 1.60 | 2.06 ± 0.90 a | 1.93 ± 0.59 a | 7.49 ± 1.01 b , c |
SPCI73TGATA1KO | 8.17 ± 0.49 | 4.66 ± 1.93 | 1.71 ± 0.55 a | 1.84 ± 0.17 a | |
B Cells B220+CX3CR1+ | SPCI73TGATA1WT | 12.03 ± 2.01 | 5.32 ± 2.19 | 1.29 ± 0.63 a | 11.15 ± 0.70 c |
SPCI73TGATA1KO | 20.18 ± 1.66 | 7.42 ± 2.27 a | 5.47 ± 2.09 a | 11.83 ± 1.07 a |
Single cell suspensions of SP-CI73TGATA1WT and SP-CI73TGATA1KO lung digests was assessed by flow cytometry, enriched in viable CD45+ singlets, and analyzed following gating strategy described in the Methods section. Relative abundance (%) is presented as means ± SEM (N=4-6 mice/condition). Data were analyzed by two-way ANOVA, with Tukey post-hoc test.
Significant compared to controls (CTL).
Significant compared to 7 d group.
Significant compared to14 d group.